Opdivo and Upper respiratory tract inflammation - a phase IV clinical study of FDA data

Summary:

Upper respiratory tract inflammation is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Pitavastatin Calcium, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Upper respiratory tract inflammation when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Upper respiratory tract inflammation?

Upper respiratory tract inflammation is found to be associated with 366 drugs and 582 conditions by eHealthMe. Check the latest studies of Upper respiratory tract inflammation.

On Aug, 11, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 13 people (0.02%) have Upper respiratory tract inflammation.

Could Opdivo cause Upper respiratory tract inflammation?

Among these 13 people:

How long have people been on Opdivo when they have Upper respiratory tract inflammation? *

What is the gender of people who have Upper respiratory tract inflammation when taking Opdivo? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Upper respiratory tract inflammation when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Upper respiratory tract inflammation? *

Malignant Neoplasm Progression (cancer tumour came back): 7 people, 53.85%
Secondary Adrenocortical Insufficiency (inadequate secretion of acth by the pituitary gland): 6 people, 46.15%
Lymphocytic Hypophysitis (inflammation of the pituitary gland): 4 people, 30.77%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 23.08%
Thyroiditis Chronic (long lasting inflammation of thyroid gland): 2 people, 15.38%
Hepatic Function Abnormal: 2 people, 15.38%
Anastomotic Stenosis: 2 people, 15.38%
Cardiac Failure: 2 people, 15.38%
Constipation: 2 people, 15.38%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 2 people, 15.38%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 30.77%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 30.77%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 30.77%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 30.77%
High Blood Pressure: 4 people, 30.77%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 30.77%
Oral Cancer (mouth cancer): 2 people, 15.38%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 2 people, 15.38%
Gastric Cancer (stomach cancer): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Upper respiratory tract inflammation?

- Check whether Upper respiratory tract inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Upper respiratory tract inflammation:

Upper respiratory tract inflammation (366 drugs)

Browse all the conditions that are associated with Upper respiratory tract inflammation:

Upper respiratory tract inflammation (582 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.